Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance

Authors

Ellen H. Nagami, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Kinna Thakarar, Division of Infectious Diseases, Maine Medical Center, Portland, Maine, USA.
Paul E. Sax, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Document Type

Article

Publication Date

2-1-2022

Journal Title

Open forum infectious diseases

Abstract

Multiclass high-level transmitted HIV drug resistance is uncommon, and the selection of the optimal initial antiretroviral drug regimen may be challenging. We report a case of extensive transmitted multiclass resistance successfully treated with dolutegravir, tenofovir, and emtricitabine even though the baseline genotype demonstrated full susceptibility to only 1 drug class, integrase strand transfer inhibitors. Our case highlights both the high resistance barrier of dolutegravir and the residual antiviral activity of nucleoside reverse transcriptase inhibitors despite extensive resistance on genotype.

ISSN

2328-8957

First Page

ofab648

Recommended Citation

Nagami EH, Thakarar K, Sax PE. Sustained HIV Viral Suppression With Dolutegravir, Tenofovir, and Emtricitabine as Initial Therapy Despite High-Level Transmitted Multiclass Resistance. Open Forum Infect Dis. 2021;9(2):ofab648. Published 2021 Dec 24. doi:10.1093/ofid/ofab648